Wednesday, October 25, 2023
Roquette, a global leader in plant-based ingredients and leading provider of pharmaceutical and nutraceutical excipients, is pleased to announce the addition of three new excipient grades to its unmatched portfolio of solutions for moisture sensitive active pharmaceutical and nutraceutical ingredients. Unveiled on-stand at CPHI Barcelona, LYCATAB® CT-LM partially pregelatinized starch, MICROCEL® 103 SD and MICROCEL® 113 SD microcrystalline cellulose offer a unique range of stabilizing and moisture protective benefits, giving pharmaceutical manufacturers the tools they need to optimize any drug delivery, regardless of production method or formulation type. The new grades are the latest addition to Roquette’s wider moisture protection portfolio – a comprehensive range of low water activity (Aw) excipients demonstrated to support successful drug development in applications featuring moisture sensitive active ingredients.
LYCATAB® CT-LM: Versatility meets moisture protection
The latest entry to Roquette’s premier pregelatinized starch range, LYCATAB® CT-LM is a multifunctional filler, binder, and disintegrant offering extremely low Aw not more than (NMT) 0.1 percent) for superior stability in solid oral preparations. Suitable for dry granulation, hard capsule filling and direct compression, with a loss on drying (LOD) NMT 7 percent, LYCATAB® CT-LM gives pharmaceutical and nutraceutical producers the freedom to innovate while keeping formulations safe from hydraulic degradation. Like the rest of the LYCATAB® portfolio, it helps streamline production processes and assure rapid disintegration in the final formulation for optimal patient experience.
MICROCEL® 103 SD and 113 SD: Consistent results, powerful performance
Roquette’s expansion of its cellulosic production capacity, following the acquisition of leading excipients manufacturer Crest Cellulose in 2022, has enabled the company to add two new grades to its already extensive MICROCEL® microcrystalline cellulose range. Optimized for roll compaction and dry granulation processes, MICROCEL® 103 SD offers consistent granulometric distribution and an Aw of NMT 0.2% for improved production efficiency and long-term product quality. MICROCEL® 113 SD is similarly primed for repeatable performance, building the benefits for moisture sensitive formulations with an Aw of NMT 0.1%. Lactose-, gluten- and sugar-free with a non-GMO positioning, both grades take hard tablet production up a gear, marrying reliability with superior stability to unlock tablets that stay effective throughout their shelf life, batch after batch.
Tackling the toughest challenges in drug delivery
In the wake of the new grade launches presented to the industry at CPHI Barcelona, Paul Smaltz, Vice President of Pharmaceutical Solutions at Roquette, comments: “Pharmaceutical and nutraceutical manufacturers have grappled with the issue of active ingredient hydrolysis and moisture-related degradation for decades. At Roquette, it’s our mission to tackle the toughest challenges in drug delivery head on through cutting-edge science and an unwavering drive to improve the experience of patients and producers. Joining the ranks of our PEARLITOL® ProTec co-processed mannitol-starch solution launched earlier this year, these new LYCATAB® and MICROCEL® grades solidify our position as the leading provider of excipients for moisture-sensitive applications. We’re delighted to be sharing this news with colleagues and customers at CPHI because it gives industry players the opportunity to discover the transformational impact of our moisture protection portfolio first-hand, straight from our experts.”
To learn more about Roquette and its comprehensive range of solutions for pharmaceutical, nutraceutical and biopharmaceutical formulations, visit: www.roquette.com.
About Roquette “Improving well-being by offering the best of nature”
Roquette is a family-owned global leader in plant-based ingredients, a pioneer of plant proteins and a leading provider of pharmaceutical excipients. Founded in 1933, the company currently operates in more than 100 countries, has a turnover of around 5 billion euros, and employs more than 8,000 people worldwide.
Life and nature have been our sources of inspiration for decades. All our raw materials are of natural origin. From them, we enable a whole new plant protein cuisine; we offer pharmaceutical solutions that play a key role in medical treatments; and we develop innovative ingredients for food, nutrition, and health markets. We truly unlock the potential of nature to improve, cure and save lives.
Thanks to a constant drive for innovation and a long-term vision, we are committed to improving the well-being of people all over the world. We put sustainable development at the heart of our concerns, while taking care of resources and territories. We are determined to create a better and healthier future for all generations.
Discover more about Roquette at this link
Media Contacts
Roquette Pharma Solutions
Sally Khalvati
[email protected]
BDB Agency
[email protected]
+44 161 925 4700
